Related Experiment Video
Updated: May 2, 2026
10:55
Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
Published on: October 31, 2025
1.1K
Angiotensin-converting enzyme insertion/deletion gene polymorphism is associated with dermatomyositis
Samuel K Shinjo1, Miyuki Uno2, Sueli M Oba-Shinjo2
1Division of Rheumatology, Universidade de São Paulo, Brazil samuel.shinjo@gmail.com.
Summary
The angiotensin-converting enzyme (ACE) D/D genotype is linked to an increased risk of developing dermatomyositis (DM). This finding suggests a potential genetic marker for DM susceptibility.
Area of Science:
- Genetics
- Immunology
- Dermatology
Background:
- Dermatomyositis (DM) pathogenesis involves vascular issues, leading to tissue damage.
- Hypothesizes a link between angiotensin-converting enzyme (ACE) gene polymorphism and DM susceptibility.
Purpose of the Study:
- To investigate the association between the ACE insertion/deletion (I/D) gene polymorphism and DM risk.
Main Methods:
- A case-control study genotyped the ACE gene in 88 DM patients and 99 healthy controls.
- ACE gene polymorphism determined using real-time PCR and melting curve analysis.
Main Results:
- The D allele frequency was higher in DM patients (63.6%) compared to controls (55.6%).
- The ACE D/D genotype showed a significant association with DM (OR 2.44, 95% CI: 1.17-4.37).
- The ACE I/D genotype was inversely associated with DM risk (OR 0.51, 95% CI: 0.28-0.93).
Conclusions:
- Homozygous ACE D/D genotype is significantly associated with increased DM risk.
- Further research is needed to confirm the role of ACE gene polymorphism in DM susceptibility.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
94
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
94
03:18Non-LTR Retrotransposons
12.4K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
12.4K
02:32Exon Recombination
3.1K
The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes.
Exon shuffling follows “splice frame rules.” Each exon...
Exon shuffling follows “splice frame rules.” Each exon...
3.1K
01:33Pleiotropy
31.2K
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
31.2K